Medtronic’s BSC 9.1S Bipolar Sealer with Cutting for Orthopaedic Surgery

Medtronic’s BSC 9.1S Bipolar Sealer with Cutting for Orthopaedic Surgery

Medtronic received FDA clearance and will begin making available in the U.S. its new Aquamantys3 BSC 9.1S Bipolar Sealer with Cutting, a device that performs haemostatic sealing and coagulation of soft tissue and bone, and allows the surgeon to use it as a cutting instrument as well.

BSC 9.1S Bipolar Sealer with Cutting zoom Medtronics BSC 9.1S Bipolar Sealer with Cutting for Orthopaedic SurgeryBy bringing two tools into one, Medtronic hopes to save time during surgery while minimizing blood loss. Not having to switch between instruments while the blood is flowing can save seconds that are particularly important.

From the announcement:

Like other devices in the Aquamantys line, the BSC 9.1S uses Transcollation® technology, a combination of radiofrequency energy and saline that has been shown to reduce blood loss and maintain patient hemoglobin levels when used during orthopaedic procedures. Reductions in blood loss during surgery have been linked to reduced blood transfusion rates and decreased hospital length of stay.

“The BSC 9.1S combining cutting and Transcollation into a single device could simplify workflow by reducing the number of tool changes and therefore may result in a time savings for the surgeon,” said Dr. Roger Emerson, a surgeon at Presbyterian Hospital, Baylor Regional Medical Center at Plano Joint Replacement Center.

MINNEAPOLIS – July 30, 2012 – Medtronic, Inc. (NYSE: MDT) announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys®3 BSC 9.1S Bipolar Sealer with Cutting, a new addition to the orthopaedic portfolio of the company’s Advanced Energy business.

The BSC 9.1S Bipolar Sealer with Cutting gives surgeons the ability to optimize efficiency in surgical cases by combining hemostatic sealing capabilities for soft tissue and bone and monopolar cutting functionality in a single device. Like other devices in the Aquamantys line, the BSC 9.1S uses Transcollation® technology, a combination of radiofrequency energy and saline that has been shown to reduce blood loss and maintain patient hemoglobin levels when used during orthopaedic procedures. Reductions in blood loss during surgery have been linked to reduced blood transfusion rates and decreased hospital length of stay.

“The BSC 9.1S combining cutting and Transcollation into a single device could simplify workflow by reducing the number of tool changes and therefore may result in a time savings for the surgeon,” said Dr. Roger Emerson, a surgeon at Presbyterian Hospital in Plano, Texas.

“We are excited to offer surgeons this new addition to our ever-growing orthopaedic portfolio of advanced energy products,” said Mark Fletcher, president of the Surgical Technologies business at Medtronic, Inc. “The BSC 9.1S utilizes the effectiveness of our patented Transcollation technology in preventing and stopping bleeding during surgery and combines it with the added benefit of integral cutting. It will deliver considerable value to surgeons, patients, and hospitals alike.”

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Source : http://wwwp.medtronic.com/Newsroom/NewsReleaseDetails.do?itemId=1343305093587&lang=en_US

Related Posts Plugin for WordPress, Blogger...
Be Sociable, Share!

About the Author

has written 1822 posts on this blog.

Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes